What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world.
We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.
With rising life-expectancy, the number of cases of dementia and related disorders is increasing. In attempts to tackle the pandemic, treatment trials are moving earlier in the disease process. CANTAB offers a battery of tests specially targeted at assessing cognition in early Alzheimer’s disease (AD), and the associated effects on cognition with drug action.
Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials.
In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT